Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen (Nasdaq: PGEN) announced that Helen Sabzevari, PhD, President and CEO, will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precigen (Nasdaq: PGEN) announced that Helen Sabzevari, PhD, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026 at 7:30 AM PT. Dr. Sabzevari will also join a fireside chat hosted by commercialization partner Eversana on January 12, 2026 at 10:30 AM PT during the Biotech Showcase (January 12–14, 2026).
Investors and other participants may view event details in the company’s Events & Presentations section at the investor website.
Details
News Market Reaction – PGEN
On Jan 6, the first trading day after this news, PGEN closed 8.85% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Q3 2025 Revenue
- $2.9M
- Reported in Q3 2025 10-Q
- Q3 Net Loss
- $146.3M
- Q3 2025 net loss driven by warrant liability change
- Cash & Investments
- $123.6M
- Balance as of Sept 30, 2025 from 10-Q
- Senior Term Loan
- $100.0M
- Five-year secured term loan supporting PAPZIMEOS launch
- Non-dilutive Facility
- $125M
- Credit facility size announced Sept 3, 2025
- SG&A Expense
- $24.0M
- Q3 2025 SG&A tied to launch preparation
- Complete Response Rate
- 83%
- 15 of 18 PAPZIMEOS responders in long-term follow-up
- Shares Outstanding
- 353,810,556
- Common shares as of Sept 30, 2025
Historical Context
-
Q3 2025 results and business update following full FDA approval of PAPZIMEOS.
-
Announcement of upcoming Q3 2025 results call and business update schedule.
-
Long-term PAPZIMEOS follow-up showing durable complete responses and reduced surgeries.
-
Up to $125M non-dilutive credit facility to support PAPZIMEOS commercialization.
-
Participation in virtual fireside chats focused on newly FDA-approved RRP therapy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biopharmaceutical medical
immuno-oncology medical
autoimmune disorders medical
infectious diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
In addition, Dr. Sabzevari will participate in a fireside chat hosted by the Company's commercialization operations partner, Eversana, on Monday, January 12, 2026 at 10:30 AM PT at the Biotech Showcase, which runs January 12–14, 2026 in
Participants may view details for these events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and the Company's other product candidates, the timing of clinical trials and their results, the Company's ability to commence clinical studies or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302652709.html
SOURCE Precigen, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.